Frequency Therapeutics completes FX-322 Phase 2b enrollment; Q3 net loss $19.5M, cash $99.3M

Korro Bio, Inc.

2023-Q3 EPS reported -$1.83

Phase 2b study of FX-322 for SNHL enrolled 142 participants; primary endpoint readout expected Q1 2023.
Second hearing restoration program FX-345 to begin Phase 1b in coming weeks; H2 2023 results expected.
MS remyelination program advanced to IND-enabling studies; IND filing planned for H2 2023.
Q3 2022 net loss $19.5M vs $25.2M in Q3 2021; R&D expenses $11.7M, down from $15.7M.
Cash, equivalents and marketable securities $99.3M; expected to fund operations into 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Korro Bio, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.

View on SEC.gov

2 earnings releases filed in the last 30 days. Browse all earnings releases →

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.